This study is currently not recruiting participants.
A Phase III Two-Part Randomized Double-blind Placebo-Controlled Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients with Rheumatoid Arthritis
Not Recruiting
18 years - 100 years
All
Phase
N/A
Brief description of study.
This study will assess the safety and efficacy of MK-0663 vs. placebo in subjects with rheumatoid arthritis
Detailed description of study
This study will assess the safety and efficacy of MK-0663 vs. placebo in subjects with rheumatoid arthritis
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Rheumatoid Arthritis
Age:
18 years - 100 years
Gender: All
Updated on
22 Oct 2013.
Study ID: MK-0663-107
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
